What was the REDUCE-IT trial?
The REDUCE-IT trial (Reduction of Cardiovascular Events With Icosapent Ethyl) was a randomized trial of 8179 patients with ASCVD including history of ischemic stroke or TIA (70%) or diabetes with other risk factors (30%) that tested the efficacy of taking IPE 2 g twice daily plus statin versus statin alone. The trial had a median follow-up of 4.9 years and revealed a 25% reduction in the primary end point of MACEs. Results for nonfatal stroke and TIA were the same for MACEs, with no difference occurring in hemorrhagic stroke. A small, significant increase in AF occurred in those treated with IPE (5.3% versus 3.9%).  